6505--VA San Diego and Phoenix Lymphoseek IDIQ

Solicitation / RFP / RFQ

This document is a solicitation for Lymphoseek, an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The purpose is to procure Lymphoseek for the VA San Diego and Phoenix facilities.

• The primary deliverable is the supply of Lymphoseek.

• Contract Type: Indefinite Delivery/Indefinite Quantity (IDIQ)

• Estimated IDV Award Amount: $258,908.72

• Note: The IDV contract itself does not obligate any funding.

• Submission and evaluation details are not provided in this excerpt.

• Not specified in this excerpt.

• The attached document referenced is "P03 J_A Lymphoseek_Redacted."

• Solicitation Number: 36C26226Q0421

• NAICS Code: 325412 (Pharmaceutical and Medicine Manufacturing)

• Product Service Code: 6505 (Medical and Surgical Equipment)

Solicitation / RFP / RFQ

This document is a Justification for Single Source Award for the procurement of 99m Tc Lymphoseek (Tilmanocept), a radioactive diagnostic agent used for sentinel lymph node biopsy and lymphatic mapping in solid tumor patients. The Department of Veterans Affairs (VA) San Diego and Phoenix Healthcare Systems require this agent to support patient care.

• Procurement of 99m Tc Lymphoseek (Tilmanocept).

• The agent is a receptor-targeted radioactive diagnostic agent.

• It is used for sentinel lymph node biopsy and lymphatic mapping.

• Period of Performance (PoP):

  • Base: 4/1/2026 - 3/31/2027
  • Option Year 1: 4/1/2027 - 3/31/2028
  • Option Year 2: 4/1/2028 - 3/31/2029
  • Option Year 3: 4/1/2028 - 3/31/2030
  • Option Year 4: 4/1/2030 - 3/31/2031

• Estimated Contract Value: The document indicates an estimated total contract cost, with a breakdown by period of performance. Specific quantities (56 EA per period) are listed.

• Contracting Activity: Department of Veterans Affairs, Veteran Integrated Service Network (VISN) 22, Network Contracting Office (NCO) 22.

This document is a justification for a single-source award, not a solicitation with submission instructions or evaluation criteria. It indicates that market research was conducted, including a SAM.gov special notice, which yielded no responses from other potential sources.

This justification is for a single-source award, indicating no set-aside is applicable. Market research for Small Business Administration (SBA) Small Business Search (SBS) identified potential SD/VOSBs, but they lacked the capability to manufacture or distribute Lymphoseek.

• Lymphoseek is a proprietary product manufactured and commercialized exclusively by Cardinal Health 414, LLC in North America under license from Navidea Biopharmaceuticals Inc.
• Cardinal Health 414, LLC has a history of successfully fulfilling similar requirements for the VA.
• No suitable alternatives were found in the Federal Supply Schedule.
• The justification is approved in accordance with FAR.

Notice of Intent to Sole Source

This document is a Notice of Intent (NOI) from the Department of Veterans Affairs, Network Contracting Office (NCO) 22, to award a sole source contract for Lymphoseek. This is not a request for competitive quotes. The government intends to award a contract to Cardinal Health 414, LLC.

• Product: 99mTC Tilmanocept (Lymphoseek®) UD 4 syringes

• NAICS Code: 325412 (Pharmaceutical Preparation Manufacturing)

• FSC Code: 6505 (Drugs and Biologicals)

• SBA Size Standard: 1,300 Employees

• Name: Cardinal Health 414, LLC

• Address: 7000 Cardinal Place, Dublin, OH 43017

• VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161

• Base Period: April 1, 2026 - March 31, 2027 (25 EA)

• Option Year 1: April 1, 2027 - March 31, 2028 (25 EA)

• Option Year 2: April 1, 2028 - March 31, 2029 (25 EA)

• Option Year 3: April 1, 2029 - March 31, 2030 (25 EA)

• Option Year 4: April 1, 2030 - March 31, 2031 (25 EA)

The VA San Diego Healthcare System Nuclear Medicine Service requires Lymphoseek for the localization of lymph nodes prior to surgery and treatment of patients with melanoma or other cancers.

• This notice is for informational purposes only. No solicitation document is available.
• Interested parties must submit a capabilities statement demonstrating they can provide the same items/services and that competition would be advantageous.
• Deadline: March 5, 2026, 10:00 AM Pacific Local Time.
• Submission Method: Via email to Hestia.Sim@va.gov with the subject line: “RESPONSE TO INTENT TO SOLE SOURCE Lymphoseek”.
• The government is not responsible for costs incurred in responding.
• A determination not to compete is solely at the government's discretion.